Evidence map›Paper›PMID 39902556›Full record

ArticleAnnals of neurology2025

Intravenous Thrombolysis in Patients Taking Direct Oral Anticoagulation Treatment Before Stroke Onset: Results from the Safe Implementations of Treatments in Stroke International Stroke Registry.

Marius Matusevicius, Malin Säflund, Maurizio Balestrino, Manuel Cappellari, Delfina Ferrandi, Abdoreza Ghoreishi, André Peeters, Viiu-Marika Rand, Manuela De Michele, Aleksandras Vilionskis and 2 more

Abstract read
In one paragraph

Article in Annals of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marius MatuseviciusDepartment of Neurology, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-2868-127X
Malin SäflundDepartment of Neurology, Karolinska University Hospital, Stockholm, Sweden.
Maurizio BalestrinoDepartment of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy.
Manuel CappellariStroke Unit-Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Delfina FerrandiSC Neurologia Azienda Ospedaliera Universitaria Santi Antonio e Biagio, Alessandria, Italy.
Abdoreza GhoreishiStroke Research Group, Vali-e-Asr Hospital, Department of Neurology and Stroke Unit, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
André PeetersDepartment of Neurology, Cliniques Universitaires St Luc, Brussels, Belgium.
Viiu-Marika RandDepartment of Neurology, North Estonia Medical Center, Tallinn, Estonia.
Manuela De MicheleHospital Policlinico Umberto I, Emergency Department, Stroke Unit, Sapienza University, Rome, Italy.
Aleksandras VilionskisClinic of Neurology and Neurosurgery, Vilnius University, Vilnius, Lithuania.
Andrea ZiniIRCCS Istituto Delle Scienze Neurologiche di Bologna, Bologna, Italy.
Niaz AhmedDepartment of Neurology, Karolinska University Hospital, Stockholm, Sweden.

Funding

Boehringer-IngelheimHjärt-LungfondenIRCCS Ospedale Policlinico San Martino in GenoaKarolinska InstitutetKommunfullmäktige, Stockholms StadMinistero della SaluteSTROKE-Riksförbundet
6 · The paper itself

Abstract

objectivesIntravenous thrombolysis (IVT) is contraindicated for acute ischemic stroke (AIS) patients taking direct oral anticoagulants (DOACs) within 48 hours before index stroke. Limited data exist on off-label use of IVT for these patients. We compared the safety and outcomes of IVT in AIS patients with DOAC treatment and patients with no OAC before index stroke.

methodsWe analyzed data from the Safe Implementations of Treatments in Stroke (SITS) International Stroke Thrombolysis Registry during 2013-2024. Outcomes were symptomatic intracerebral hemorrhage (SICH) by the SITS Monitoring Study and European Cooperative Acute Stroke Study II definitions, functional independency (modified Rankin Scale score 0-2), and death by 3 months. Propensity score matching with a nearest neighbor matching algorithm with a ratio of 1:2 was used for relevant clinical variables. We also analyzed the time from last DOAC dose to IVT treatment.

resultsA total of 1,311 DOAC and 129,384 no OAC patients were included. We matched 894 patients with DOAC to 1,788 with no OAC. The mean age was 75 years versus 76 years, and the median National Institutes of Health Stroke Scale score 11 versus 12, respectively. Patients with DOAC had a similar proportion of outcomes compared with patients with no OAC: SICH per SITS Monitoring Study (1.1 vs 1.5%, p = 0.50), SICH per European Cooperative Acute Stroke Study II (4.0 vs 4.3%, p = 0.82), any parenchymal hematoma (6.3 vs 7.8, p = 0.22), and functional independency (47.9 vs 46.4%, p = 0.59) and death (25.1 vs 24.0%, p = 0.65) at 3-month follow-up. The time from last DOAC dose to IVT did not affect outcomes.

interpretationIn this observational study, we did not find any difference in outcomes after IVT therapy in AIS patients with DOAC compared with no OAC treatment before index stroke. ANN NEUROL 2025;97:1205-1214.

Indexed as

AnticoagulantsFibrinolytic AgentsIschemic StrokeStrokeThrombolytic TherapyAdministration, IntravenousAdministration, OralAgedAged, 80 and overCerebral HemorrhageFemaleHumansMaleMiddle AgedRegistriesTreatment OutcomeAnticoagulantsFibrinolytic Agents

Identifiers

PMID39902556
PMCPMC12082013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.